ArticleFrontiers in oncology2025
Radiomics model based on dual-energy CT venous phase parameters to predict Ki-67 levels in gastrointestinal stromal tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Radiomics analysis of dual-layer spectral detector CT-derived iodine density maps for predicting the pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.European journal of radiology open · 2026Article
- Radiomics analysis of energy CT-derived iodine density maps for predicting lymph node metastasis in colorectal cancer.Quantitative imaging in medicine and surgery · 2026Article
- Research progress on the application of dual energy CT in gastric diseases.Frontiers in medicine · 2026Review
- Uncovering the associative mediation pathway from EUS features to malignancy through pathological mediators in gastrointestinal stromal tumor.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a radiomics model based on the features of the Dual-Energy CT (DECT) venous phase iodine density maps and effective atomic number maps to predict Ki-67 expression levels in gastrointestinal stromal tumors (GISTs). Methods: A total of 91 patients with GIST were retrospectively analyzed, including 69 patients with low Ki-67 expression (≤5%) and 22 patients with high Ki-67 expression (>5%). Four clinical features (gender, age, maximum tumor diameter, and tumor location) were extracted to construct a clinical model. The venous phase enhanced CT iodine density maps and effective atomic number maps of DSCT were used to build radiomics models. Logistic regression was used to combine radiomics features with clinical features to build a combined model. Finally, the optimal model's discrimination, calibration, and clinical decision curve were validated using the Bootstrap method. Results: The combined model was identified as the best model, with high predictive performance. The model's discrimination had an AUC of 0.982 (95% CI, 0.9603-1). The calibration test showed a Hosmer-Lemeshow test P-value of 0.99. The clinical decision curve demonstrated a probability threshold range of 15% to 98%, with a high net benefit. Conclusion: The nomogram model combining clinical features and radiomics (iodine density map radscore + effective atomic number map radscore) has the highest accuracy for preoperative prediction of Ki-67 expression in GISTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.